Major response to imatinib mesylate in KIT-muta... [J Clin Oncol. 2008] - PubMed

loading

Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene. [J Invest Dermatol. 2010]
Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene.
Terheyden P, Houben R, Pajouh P, Thorns C, Zillikens D, Becker JC. J Invest Dermatol. 2010 Jan; 130(1):314-6.
Imatinib in melanoma: a selective treatment option based on KIT mutation status? [J Clin Oncol. 2007]
Imatinib in melanoma: a selective treatment option based on KIT mutation status?
Becker JC, Bröcker EB, Schadendorf D, Ugurel S. J Clin Oncol. 2007 Mar 1; 25(7):e9.
Tumour heterogeneity of mucosal melanomas during treatment with imatinib. [Br J Dermatol. 2011]
Tumour heterogeneity of mucosal melanomas during treatment with imatinib.
Schoenewolf NL, Urosevic-Maiwald M, Dummer R. Br J Dermatol. 2011 Aug; 165(2):419-24.
Review Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature. [Dermatology. 2010]
Review Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
Satzger I, Küttler U, Völker B, Schenck F, Kapp A, Gutzmer R. Dermatology. 2010; 220(1):77-81. Epub 2009 Dec 9.
Review Multidisciplinary treatment of gastrointestinal stromal tumors. [Surg Clin North Am. 2009]
Review Multidisciplinary treatment of gastrointestinal stromal tumors.
Kingham TP, DeMatteo RP. Surg Clin North Am. 2009 Feb; 89(1):217-33, x.

Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. [Front Oncol. 2013]
Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring.
Klinac D, Gray ES, Millward M, Ziman M. Front Oncol. 2013; 3:54. Epub 2013 Mar 19.
The evolution in melanoma treatment as a reflection of precision-oriented medicine. [Oncol Lett. 2013]
The evolution in melanoma treatment as a reflection of precision-oriented medicine.
Kushnir I, Merimsky O. Oncol Lett. 2013 Feb; 5(2):424-426. Epub 2012 Dec 5.
New treatment approaches in melanoma: current research and clinical prospects. [Ther Adv Med Oncol. 2013]
New treatment approaches in melanoma: current research and clinical prospects.
Rughani MG, Gupta A, Middleton MR. Ther Adv Med Oncol. 2013 Jan; 5(1):73-80.

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Major response to imatinib mesylate in KIT-mutated melanoma.
Major response to imatinib mesylate in KIT-mutated melanoma.
J Clin Oncol. 2008 Apr 20 ;26(12):2046-51. doi: 10.1200/JCO.2007.14.0707.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

PubMed